Comparative Pharmacology
Head-to-head clinical analysis: ELTROMBOPAG versus ELTROMBOPAG OLAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELTROMBOPAG versus ELTROMBOPAG OLAMINE.
ELTROMBOPAG vs ELTROMBOPAG OLAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Eltrombopag is a small-molecule agonist of the thrombopoietin (TPO) receptor, activating the JAK/STAT signaling pathway to stimulate megakaryocyte proliferation and differentiation, thereby increasing platelet production.
Thrombopoietin receptor agonist that binds to and activates the thrombopoietin receptor (c-Mpl), leading to increased proliferation and differentiation of megakaryocytes and subsequent platelet production.
50 mg orally once daily; adjust dose based on platelet response. Maximum dose 75 mg/day.
50 mg orally once daily; for patients of East Asian ancestry with ITP, start at 25 mg orally once daily. Dose adjustments based on platelet counts: increase up to 75 mg daily or decrease to 25 mg daily as needed.
None Documented
None Documented
Clinical Note
moderateEltrombopag + Deferasirox
"The serum concentration of Deferasirox can be increased when it is combined with Eltrombopag."
Clinical Note
moderateEltrombopag + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Eltrombopag."
Clinical Note
moderateEltrombopag + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Eltrombopag."
Clinical Note
moderateEltrombopag + Ticlopidine
~21–32 hours in healthy subjects; 26–35 hours in ITP patients. Supports once-daily dosing.
Terminal elimination half-life is approximately 21–32 hours (mean ~29 hours) in healthy subjects. At steady state, clinically relevant due to once-daily dosing with delayed platelet response.
Fecal (≥59% as unchanged drug, ~31% as metabolites); renal (~20% as metabolites, <1% as unchanged drug). Total excretion: feces ~88%, urine ~13%.
Primarily fecal (59%) and renal (31%), with unchanged drug representing <1% in urine and ~20% in feces; biliary elimination accounts for most of the fecal route.
Category C
Category C
Thrombopoietin Receptor Agonist
Thrombopoietin Receptor Agonist
"The metabolism of Ticlopidine can be decreased when combined with Eltrombopag."